Cytosolic PLA 2 is required for CTL- Mediated immunopathology of celiac disease via NKG2D and IL-15

Journal of Experimental Medicine

Volumn 206, Issue 3, 2009, Pages 707-719

  Tang, Fangming ^a   Chen, Zhangguo ^a   Ciszewski, Cezary ^a   Setty, Mala ^a   Solus, Jason ^a   Tretiakova, Maria ^a   Ebert, Ellen ^b   Han, Jin ^a   Lin, Anning ^a   Guandalini, Stefano ^a   Groh, Veronika ^c   Spies, Thomas ^c   Green, Peter ^d   Jabri, Bana ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CYTOSOLIC PHOSPHOLIPASE A2; INTERLEUKIN 15; MITOGEN ACTIVATED PROTEIN KINASE; NATURAL KILLER CELL RECEPTOR NKG2D; STRESS ACTIVATED PROTEIN KINASE; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ARTICLE; CELIAC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; IN VIVO STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; BIOLOGICAL MODEL; CYTOTOXICITY; DEGRANULATION; ENZYMOLOGY; EPITHELIUM CELL; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; UPREGULATION;

ARACHIDONIC ACID; CELIAC DISEASE; CELL DEGRANULATION; CYTOTOXICITY, IMMUNOLOGIC; ENZYME ACTIVATION; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTERLEUKIN-15; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, IMMUNOLOGICAL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PHOSPHOLIPASES A2, CYTOSOLIC; PHOSPHORYLATION; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 63449087957     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20071887     Document Type: Article

References (88)

1. Bauer, S., V. Groh, J. Wu, A. Steinle, J.H. Phillips, L.L. Lanier, and T. Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress- inducible MICA. Science. 285:727-729.
2. Cosman, D., J. Mullberg, C.L. Sutherland, W. Chin, R. Armitage, W. Fanslow, M. Kubin, and N.J. Chalupny. 2001. ULBPs, Novel MHC Class I-Related Molecules, Bind to CMV Glycoprotein UL16 and Stimulate NK Cytotoxicity through the NKG2D Receptor. Immunity. 14:123-133.
3. Chalupny, N.J., C.L. Sutherland, W.A. Lawrence, A. Rein-Weston, and D. Cosman. 2003. ULBP4 is a novel ligand for human NKG2D. Biochem. Biophys. Res. Commun. 305:129-135.
4. Diefenbach, A., E.R. Jensen, A.M. Jamieson, and D.H. Raulet. 2001. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 413:165-171.
5. Groh, V., J. Wu, C. Yee, and T. Spies. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 419:734-738.
6. Meresse, B., Z. Chen, C. Ciszewski, M. Tretiakova, G. Bhagat, T.N. Krausz, D.H. Raulet, L.L. Lanier, V. Groh, T. Spies, et al. 2004. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity. 21:357-366.
7. Hue, S., J.J. Mention, R.C. Monteiro, S. Zhang, C. Cellier, J. Schmitz, V. Verkarre, N. Fodil, S. Bahram, N. Cerf-Bensussan, and S. Caillat- Zucman. 2004. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity. 21:367-377.
8. Groh, V., A. Bruhl, H. El-Gabalawy, J.L. Nelson, and T. Spies. 2003. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA. 100:9452-9457.
9. Ogasawara, K., J.A. Hamerman, L.R. Ehrlich, H. Bour-Jordan, P. Santamaria, J.A. Bluestone, and L.L. Lanier. 2004. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity. 20:757-767.
10. Wu, J., Y. Song, A.B. Bakker, S. Bauer, T. Spies, L.L. Lanier, and J.H. Phillips. 1999. An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 285:730-732.
11. Rosen, D.B., M. Araki, J.A. Hamerman, T. Chen, T. Yamamura, and L.L. Lanier. 2004. A Structural basis for the association of DAP12 with mouse, but not human, NKG2D. J. Immunol. 173:2470-2478.
12. Andre, P., R. Castriconi, M. Espeli, N. Anfossi, T. Juarez, S. Hue, H. Conway, F. Romagne, A. Dondero, M. Nanni, et al. 2004. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur. J. Immunol. 34:961-971.
13. Roberts, A.I., L. Lee, E. Schwarz, V. Groh, T. Spies, E.C. Ebert, and B. Jabri. 2001. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J. Immunol. 167:5527-5530.
14. Verneris, M.R., M. Karami, J. Baker, A. J ayaswal, and R.S. Negrin. 2004. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 103:3065-3072.
15. Jabri, B., and B. Meresse. 2006. NKG2 receptor-mediated regulation of effector CTL functions in the human tissue microenvironment. Curr. Top. Microbiol. Immunol. 298:139-156.
16. Bonventre, J. 2004. Cytosolic phospholipase A2alpha reigns supreme in arthritis and bone resorption. Trends Immunol. 25:116-119.
17. Marusic, S., M.W. Leach, J.W. Pelker, M.L. Azoitei, N. Uozumi, J. Cui, M.W. Shen, C.M. DeClercq, J.S. Miyashiro, B.A. Carito, et al. 2005. Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis. J. Exp. Med. 202:841-851.
18. Werz, O. 2002. 5-lipoxygenase: cellular biology and molecular pharmacology. Curr. Drug Targets Inflamm. Allergy. 1:23-44.
19. Burgermeister, E., J. Endl, and W.V. Scheuer. 2003. Activation of cytosolic phospholipase A2 in human T-lymphocytes involves inhibi- tor-kappaB and mitogen-activated protein kinases. Eur. J. Pharmacol. 466:169-180.
20. Tessier, C., A. Hichami, and N.A. Khan. 2002. Implication of three isoforms of PLA(2) in human T-cell proliferation. FEBS Lett. 520:111-116.
21. Farooqui, A.A., L.A. Horrocks, and T. Farooqui. 2000. Deacylation and reacylation of neural membrane glycerophospholipids. J. Mol. Neurosci. 14:123-135.
22. Ray, P., H. Ishida, C.B. Millard, J.P. Petrali, and R. Ray. 1999. Phospholipaise A2 and arachidonic acid-mediated mechanism of neu-roexocytosis: a possible target of botidinum neurotoxin A other then SNAP-25. J. Appl. Toxicol. 19(Suppl 1):S27-S28.
23. Juhl, K., A.M. Efanov, H.L. Olsen, and J. Gromada. 2003. Secretory phospholipase A2 is released from pancreatic beta-cells and stimulates insulin secretion via inhibition of ATP-dependent K+ channels. Biochem. Biophys. Res. Commun. 310:274-279.
24. Nakatani, N., N. Uozumi, K. Kume, M. Murakami, I. Kudo, and T. Shimizu. 2000. Role of cytosolic phospholipase A2 in the production of lipid mediators and histamine release in mouse bone-marrow-derived mast cells. Biochem. J. 352(Pt 2):311-317.
25. Veien, M., F. Szlam, J.T. Holden, K. Yamaguchi, D.D. Denson, and J.H. Levy. 2000. Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mast cells. Anesthesiology. 92:1074-1081.
26. Henderson, L.M., S.K. Moule, and J.B. Chappell. 1993. The immediate activator of the NADPH oxidase is arachidonate not phosphorylation. Eur. J. Biochem. 211:157-162.
27. White, S.R., M.E. Strek, G.V. Kulp, S.M. Spaethe, R.A. Burch, S.P. Neeley, and A.R. Leff. 1993. Regulation of human eosinophil degranu- lation and activation by endogenous phospholipase A2. J. Clin. Invest. 91:2118-2125.
28. Chakraborti, S. 2003. Phospholipase A2 isoforms: a perspective. Cell. Signal. 15:637-665.
29. Groh, V., R. Rhinehart, J. Randolph-Habecker, M.S. Topp, S.R. Riddell, and T. Spies. 2001. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2:255-260.
30. Gilbert, J.J., A. Stewart, C.A. Courtney, M.C. Fleming, P. Reid, C.G. Jackson, A. Wise, M.J. Wakelam, and M.M. Harnett. 1996. Antigen receptors on immature, but not mature, B and T cells are coupled to cy- tosolic phospholipase A2 activation: expression and activation of cytosolic phospholipase A2 correlate with lymphocyte maturation. J. Immunol. 156:2054-2061.
31. Jabri, B., J.M. Selby, H. Negulescu, L. Lee, A.I. Roberts, A. Beavis, M. Lopez-Botet, E.C. Ebert, and R.J. Winchester. 2002. TCR specificity dictates CD94/NKG2A expression by human CTL. Immunity. 17:487-499.
32. Crespo, P., X.R. Bustelo, D.S. Aaronson, O.A. Coso, M. Lopez-Barahona, M. Barbacid, and J.S. Gutkind. 1996. Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav. Oncogene. 13:455-460.
33. Billadeau, D.D., J.L. Upshaw, R.A. Schoon, C.J. Dick, and P.J. Leibson. 2003. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat. Immunol. 4:557-564.
34. Upshaw, J.L., L.N. Arneson, R.A. Schoon, C.J. Dick, D.D. Billadeau, and P.J. Leibson. 2006. NKG2D-mediated signaling requires a DAP10- bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat. Immunol. 7:524-532.
35. Tang, F., G. Tang, J. Xiang, Q. Dai, M.R. Rosner, and A. Lin. 2002. The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosis. Mol. Cell. Biol. 22:8571-8579.
36. Kuo, W.L., M. Abe, J. Rhee, E.M. Eves, S.A. McCarthy, M. Yan, D.J. Templeton, M. McMahon, and M.R. Rosner. 1996. Raf, but not MEK or ERK, is sufficient for differentiation of hippocampal neuronal cells. Mol. Cell. Biol. 16:1458-1470.
37. Yan, M., and D.J. Templeton. 1994. Identification of 2 serine residues of MEK-1 that are differentially phosphorylated during activation by raf and MEK kinase. J. Biol. Chem. 269:19067-19073.
38. Benahmed, M., B. Meresse, B. Arnulf, U. Barbe, J.J. Mention, V. Verkarre, M. Allez, C. Cellier, O. Hermine, and N. Cerf-Bensussan. 2007. Inhibition of TGF-beta signaling by IL-15: a new role for IL- 15 in the loss of immune homeostasis in celiac disease. Gastroenterology. 132:994-1008.
39. Gao, Z.H., M.S. Tretiakova, W.H. Liu, C. Gong, P.D. Farris, and J. Hart. 2006. Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma. Mod. Pathol. 19:533-540.
40. Cregger, M., A.J. Berger, and D.L. Rimm. 2006. Immunohistochemistry and quantitative analysis of protein expression. Arch. Pathol. Lab. Med. 130:1026-1030.
41. Jabri, B., N.P. de Serre, C. Cellier, K. Evans, C. Gache, C. Carvalho, J.F. Mougenot, M. Allez, R. Jian, P. Desreumaux, et al. 2000. Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology. 118:867-879.
42. Jackson, M.B., and E.R. Chapman. 2006. Fusion pores and fusion machines in Ca2+-triggered exocytosis. Annu. Rev. Biophys. Biomol. Struct. 35:135-160.
43. Hille, B., J. Billiard, D.F. Babcock, T. Nguyen, and D.S. Koh. 1999. Stimulation of exocytosis without a calcium signal. J. Physiol. 520(Pt1):23-31.
44. Creutz, C.E. 1981. cis-Unsaturated fatty acids induce the fusion of chromaffin granules aggregated by synexin. J. Cell Biol. 91:247-256.
45. Blackwood, R.A., A.T. Transue, D.M. Harsh, R.C. Brower, S.J. Zacharek, J.E. Smolen, and R.J. Hessler. 1996. PLA2 promotes fusion between PMN- specific granules and complex liposomes. J. Leukoc. Biol. 59:663-670.
46. Ong, W.L., B. Jiang, N. Tang, S.F. Ling, J.F. Yeo, S. Wei, A.A. Farooqui, and W.Y. Ong. 2006. Differential effects of polyunsaturated fatty acids on membrane capacitance and exocytosis in rat pheochromo- cytoma-12 cells. Neurochem. Res. 31:41-48.
47. Khurana, D., L.N. Arneson, R.A. Schoon, C.J. Dick, and P.J. Leibson. 2007. Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk. J. Immunol. 178:3575-3582.
48. Hoffman, T., F. Hirata, P. Bougnoux, B.A. Fraser, R.H. Goldfarb, R.B. Herberman, and J. Axelrod. 1981. Phospholipid methylation and phospholipase A2 activation in cytotoxicity by human natural killer cells. Proc. Natl. Acad. Sci. USA. 78:3839-3843.
49. Jondal, M., C. Kullman, P. Rossi, and J.A. Lindgren. 1985. Second messenger function of arachidonic acid lipoxygenation products in human natural killer cell lysis? Scand.J. Immunol. 22:285-293.
50. Carine, K., and D. Hudig. 1984. Assessment of a role for phospholipase A2 and arachidonic acid metabolism in human lymphocyte natural cytotoxicity. Cell. Immunol. 87:270-283.
51. Leung, K.H., M.M. Ip, and H.S. Koren. 1986. Regulation of human natural killing. IV. Role of lipoxygenase in regulation of natural killing activity. Scand. J. Immunol. 24:371-380.
52. Sibbitt, W.L. Jr., T. Imir, and A.D. Bankhurst. 1986. Reversible inhibition of lymphokine-activated killer cell activity by lipoxygenase-path- way inhibitors. Int. J. Cancer. 38:517-521.
53. Grazia Cifone, M., P. Roncaioli, L. Cironi, C. Festuccia, A. Meccia, S. D'Alo, D. Botti, and A. Santoni. 1997. NKR-P1A stimulation of ara- chidonate-generating enzymes in rat NK cells is associated with granule release and cytotoxic activity. J. Immunol. 159:309-317.
54. Aldemir, H., V. Prod'homme, M.J. Dumaurier, C. Retiere, G. Poupon, J. Cazareth, F. Bihl, and V.M. Braud. 2005. Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J. Immunol. 175:7791-7795.
55. Rosen, D.B., J. Bettadapura, M. Alsharifi, P.A. Mathew, H.S. Warren, and L.L. Lanier. 2005. Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J. Immunol. 175:7796-7799.
56. Milella, M., A. Gismondi, P. Roncaioli, L. Bisogno, G. Palmieri, L. Frati, M.G. Cifone, and A. Santoni. 1997. CD16 cross-linking induces both secretory and extracellular signal-regulated kinase (ERK)-dependent cytosolic phospholipase A2 (PLA2) activity in human natural killer cells: involvement of ERK, but not PLA2, in CD16-triggered granule exocytosis. J. Immunol. 158:3148-3154.
57. Ehrlich, L.I., K. Ogasawara, J.A. Hamerman, R. Takaki, A. Zingoni, J.P. Allison, and L.L. Lanier. 2005. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J. Immunol. 174:1922-1931.
58. Bryceson, Y.T., M.E. March, D.F. Barber, H.G. Ljunggren, and E.O. Long. 2005. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J. Exp. Med. 202:1001-1012.
59. Bryceson, Y.T., M.E. March, H.G. Ljunggren, and E.O. Long. 2006. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 107:159-166.
60. Upshaw, J.L., and P.J. Leibson. 2006. NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes. Semin. Immunol. 18:167-175.
61. Upshaw, J.L., R.A. Schoon, C.J. Dick, D.D. Billadeau, and P.J. Leibson. 2005. The isoforms of phospholipase C-gamma are differentially used by distinct human NK activating receptors. J. Immunol. 175:213-218.
62. Jiang, K., B. Zhong, D.L. Gilvary, B.C. Corliss, E. Hong-Geller, S. Wei, and J.Y. Djeu. 2000. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat. Immunol. 1:419-425.
63. Chen, X., P.P. Trivedi, B. Ge, K. Krzewski, and J.L. Strominger. 2007. Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity. Proc. Natl. Acad. Sci. USA. 104:6329-6334.
64. Cella, M., K. Fujikawa, I. Tassi, S. Kim, K. Latinis, S. Nishi, W. Yokoyama, M. Colonna, and W. Swat. 2004. Differential requirements for Vav proteins in DAP10- and ITAM-mediated NK cell cytotoxicity. J. Exp. Med. 200:817-823.
65. Chan, G., T. Hanke, and K.D. Fischer. 2001. Vav-1 regulates NK T cell development and NK cell cytotoxicity. Eur. J. Immunol. 31: 2403-2410.
66. Galandrini, R., G. Palmieri, M. Piccoli, L. Frati, and A. Santoni. 1999. Role for the Rac1 exchange factor Vav in the signaling pathways leading to NK cell cytotoxicity. J. Immunol. 162:3148-3152.
67. Graham, D.B., M. Cella, E. Giurisato, K. Fujikawa, A.V. Miletic, T. Kloeppel, K. Brim, T. Takai, A.S. Shaw, M. Colonna, and W. Swat. 2006. Vav1 controls DAP10-mediated natural cytotoxicity by regulating actin and microtubule dynamics. J. Immunol. 177:2349-2355.
68. Colucci, F., E. Rosmaraki, S. Bregenholt, S.I. Samson, V. Di Bartolo, M. Turner, L. Vanes, V. Tybulewicz, and J.P. Di Santo. 2001. Functional dichotomy in natural killer cell signaling: Vav1-dependent and -independent mechanisms. J. Exp. Med. 193:1413-1424.
69. Gagnon, L., M. Girard, A.K. Sullivan, and M. Rola-Pleszczynski. 1987. Augmentation of human natural cytotoxic cell activity by leukotriene B4 mediated by enhanced effector-target cell binding and increased lytic efficiency. Cell. Immunol. 110:243-252.
70. Rossi, P., J.A. Lindgren, C. Kullman, and M. J ondal. 1985. Products of the lipoxygenase pathway in human natural killer cell cytotoxicity. Cell. Immunol. 93:1-8.
71. Green, P.H., and B. Jabri. 2003. Coeliac disease. Lancet. 362:383-391.
72. Sollid, L.M., and B. Jabri. 2005. Is celiac disease an autoimmune disorder? Curr. Opin. Immunol. 17:595-600.
73. Sollid, L.M. 2002. Coeliac disease: dissecting a complex inflammatory disorder. Nat. Rev. Immunol. 2:647-655.
74. Reinecker, H.C., R.P. MacDermott, S. Mirau, A. Dignass, and D.K. Podolsky. 1996. Intestinal epithelial cells both express and respond to inter- leukin 15. Gastroenterology. 111:1706-1713.
75. 4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J. Exp. Med. 203:829-835.
76. Cherny, V.V., L.M. Henderson, W. Xu, L.L. Thomas, and T.E. DeCoursey. 2001. Activation of NADPH oxidase-related proton and electron currents in human eosinophils by arachidonic acid. J. Physiol. 535:783-794.
77. Louis, N.A., K.E. Hamilton, and S.P. Colgan. 2005. Lipid mediator networks and leukocyte transmigration. Prostaglandins Leukot. Essent. Fatty Acids. 73:197-202.
78. Nakano, N., A. Nakao, T. Uchida, N. Shirasaka, H. Yoshizumi, K. Okumura, R. Tsuboi, and H. Ogawa. 2005. Effects of arachidonic acid analogs on FcepsilonRI-mediated activation of mast cells. Biochim. Biophys. Acta. 1738:19-28.
79. Valone, F.H. 1984. Regulation of human leukocyte function by lipoxygen- ase products of arachidonic acid. Contemp. Top. Immunobiol. 14:155-170.
80. Kasama, T., Y. Miwa, T. Isozaki, T. Odai, M. Adachi, and S.L. Kunkel. 2005. Neutrophil-derived cytokines: potential therapeutic targets in inflammation. Curr. Drug Targets Inflamm. Allergy. 4:273-279.
81. Chen, M., B.K. Lam, Y. Kanaoka, P.A. Nigrovic, L.P. Audoly, K.F. Austen, and D.M. Lee. 2006. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J. Exp. Med. 203:837-842.
82. Colombel, J.F., A. Janin, and G. Torpier. 1990. Activated eosinophils in coeliac disease. Gut. 31:583-584.
83. Hallgren, R., J.F. Colombel, R. Dahl, K. Fredens, A. Kruse, N.O. Jacobsen, P. Venge, and J.C. Rambaud. 1989. Neutrophil and eosino- phil involvement of the small bowel in patients with celiac disease and Crohn's disease: studies on the secretion rate and immunohistochemical localization of granulocyte granule constituents. Am. J. Med. 86:56-64.
84. Horvath, K., K. Simon, G. Horn, and H. Bodanszky. 1986. Mast cell degranulation after a single dose of gliadin in the jejunum of patients with coeliac disease. Acta. Paediatr. Hung. 27:311-316.
85. Roder, J.C., and M. Klein. 1979. Target-effector interaction in the natural killer cell system. IV. Modulation by cyclic nucleotides. J. Immunol. 123:2785-2790.
86. Bankhurst, A.D. 1982. The modulation of human natural killer cell activity by prostaglandins. J. Clin. Lab. Immunol. 7:85-91.
87. Bosetti, F., R. Langenbach, and G.R. Weerasinghe. 2004. Prostaglandin E2 and microsomal prostaglandin E synthase-2 expression are decreased in the cyclooxygenase-2-deficient mouse brain despite compensatory induction of cyclooxygenase-1 and Ca2+-dependent phospholipase A2. J. Neurochem. 91:1389-1397.
88. McGargill, M.A., B.G. Wen, C.M. Walsh, and S.M. Hedrick. 2004. A deficiency in Drak2 results in a T cell hypersensitivity and an unexpected resistance to autoimmunity. Immunity. 21:781-791.